Literature DB >> 1194279

Isolation and characterization of band 3, the predominant polypeptide of the human erythrocyte membrane.

J Yu, T L Steck.   

Abstract

Band 3 is the predominant approximately 90,000-dalton polypeptide component of the human erythrocyte membrane. It was solubilized selectively, along with the other major glycoproteins, by extracting membrane ghosts with Triton X-100 under nondenaturing conditions. Two major polypeptides remained associated with Band 3 under these conditions; however one (Band 6) could be dissociated at an ionic strength of 0.15 and the other (Band 4.2) by treatment with p-chloromercuribenzoate. Band 3 was then purified (greater than or equal to 97%) by aminoethyl cellulose ion exchange chromatography. The isolated protein was free of phospholipid and was moderately enriched in apolar amino acid residues; it contained galactose and glucosamine but very little sialic acid and galactosamine. When Band 3 was labeled by treatment of ghosts with galactose oxidase plus KB3H4 and then purified, the electrophoretic mobility of its radioactivity lagged slightly behing that of its Coomassie blue staining profile. Variation in glycosylation could therefore cause the diffuse trailing zone characteristically observed for Band 3 on polyacrylamide gel electrophoresis in sodium dodecyl sulfate. The ultraviolet circular dichroism of Band 3 was stable in nonionic detergent and suggested an alpha helix content of 43%, a value close to that estimated for this polypeptide in the membrane.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1194279

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Chloride channel activity of ClC-2 is modified by the actin cytoskeleton.

Authors:  N Ahmed; M Ramjeesingh; S Wong; A Varga; E Garami; C E Bear
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

2.  A monoclonal antibody monitoring band 3 modifications in human red blood cells.

Authors:  A Giuliani; S Marini; L Ferroni; P Caprari; S G Condò; M T Ramacci; B Giardina
Journal:  Mol Cell Biochem       Date:  1992-11-04       Impact factor: 3.396

3.  Reconstitution of intramembrane particles in recombinants of erythrocyte protein band 3 and lipid: effects of spectrin-actin association.

Authors:  J Yu; D Branton
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

4.  Proteome analysis of the triton-insoluble erythrocyte membrane skeleton.

Authors:  Avik Basu; Sandra Harper; Esther N Pesciotta; Kaye D Speicher; Abhijit Chakrabarti; David W Speicher
Journal:  J Proteomics       Date:  2015-08-10       Impact factor: 4.044

5.  Purification of rat intestinal maltase/glucoamylase and its anomalous dissociation either by heat or by low pH.

Authors:  P R Flanagan; G G Forstner
Journal:  Biochem J       Date:  1978-08-01       Impact factor: 3.857

6.  High affinity ligands from in vitro selection: complex targets.

Authors:  K N Morris; K B Jensen; C M Julin; M Weil; L Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

7.  Some observations on the choice of detergent for solubilization of the human erythrocyte membrane.

Authors:  D A Grant; S Hjertén
Journal:  Biochem J       Date:  1977-05-15       Impact factor: 3.857

8.  Regulation of the interaction of purified human erythrocyte AMP deaminase and the human erythrocyte membrane.

Authors:  G M Pipoly; G R Nathans; D Chang; T F Deuel
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

9.  Senescent cell antigen is immunologically related to band 3.

Authors:  M M Kay; S R Goodman; K Sorensen; C F Whitfield; P Wong; L Zaki; V Rudloff
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

10.  Water exchange through erythrocyte membranes: nuclear magnetic resonance studies on the effects of inhibitors and of chemical modifications of human membranes.

Authors:  G Benga; V I Pop; O Popescu; M Ionescu; V Mihele
Journal:  J Membr Biol       Date:  1983       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.